TARDBP Inhibitors

TARDBP inhibitors, short for TAR DNA-binding protein inhibitors, belong to a specific chemical class designed to target the TARDBP protein, also known as TDP-43. TDP-43 is a multifunctional nuclear protein found predominantly in the cell nucleus, where it plays a pivotal role in regulating gene expression and RNA processing. However, abnormal accumulation of TDP-43 in the cytoplasm of neurons is a hallmark of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). This mislocalization of TDP-43 is associated with cellular dysfunction and has been implicated in the pathogenesis of these disorders. Therefore, TARDBP inhibitors are a class of molecules designed to modulate the activity or expression of TDP-43 with the aim of mitigating its aberrant cytoplasmic aggregation and subsequent cellular toxicity.

TARDBP inhibitors encompass a diverse range of compounds, including small molecules and biologics, which can act through various mechanisms to interfere with TDP-43 function. Some inhibitors may target the transcriptional regulation of TARDBP itself, aiming to reduce the overall production of TDP-43 in cells. Others may focus on preventing the abnormal post-translational modifications or misfolding of TDP-43 that lead to its cytoplasmic accumulation. Additionally, some TARDBP inhibitors may promote the clearance of aggregated TDP-43 from cells or enhance its degradation processes. By modulating TDP-43 in these ways, TARDBP inhibitors have the ability to address one of the underlying molecular abnormalities observed in ALS and FTLD, although their precise mechanisms of action and efficacy are still subjects of ongoing research and exploration.